Novartis partner Artios bags megaround to drive clinical work on DNA damage repair factors
Biopharma is constantly on the hunt for the next generation of targeted oncology drugs to effectively wipe out cancer cells. But to keep those tumors gone, biotechs like Artios, now the recipient of a fundraising megaround, are using the cells’ own damage repair mechanisms against them.
Artios Pharma has snagged a $153 million C round to help drive the UK-based biotech’s lead candidates targeting DNA damage repair factors — proteins that help knit together damaged DNA — through the clinic, the biotech said Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.